Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.

Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Masson Hinrichs MJ, Bezabeh BZ, Fleming RL, Dimasi N, Feng H, Toader D, Yuan AQ, Xu L, Lin J, Gao C, Wu H, Dixit R, Osbourn JK, Coats SR.

Cancer Cell. 2019 Jun 10;35(6):948-949. doi: 10.1016/j.ccell.2019.05.010. No abstract available.

PMID:
31185215
2.

Characterization of Disulfide Bond Rebridged Fab-Drug Conjugates Prepared Using a Dual Maleimide Pyrrolobenzodiazepine Cytotoxic Payload.

Ruddle BT, Fleming R, Wu H, Gao C, Dimasi N.

ChemMedChem. 2019 Jun 18;14(12):1185-1195. doi: 10.1002/cmdc.201900077. Epub 2019 May 3.

PMID:
30980702
3.

Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.

White JB, Fleming R, Masterson L, Ruddle BT, Zhong H, Fazenbaker C, Strout P, Rosenthal K, Reed M, Muniz-Medina V, Howard P, Dixit R, Wu H, Hinrichs MJ, Gao C, Dimasi N.

MAbs. 2019 Apr;11(3):500-515. doi: 10.1080/19420862.2019.1578611. Epub 2019 Mar 5.

PMID:
30835621
4.

Characterization and in vitro data of antibody drug conjugates (ADCs) derived from heterotrifunctional linker designed for the site-specific preparation of dual ADCs.

Kumar A, Kinneer K, Masterson L, Ezeadi E, Howard P, Wu H, Gao C, Dimasi N.

Data Brief. 2018 Nov 6;21:2208-2220. doi: 10.1016/j.dib.2018.11.005. eCollection 2018 Dec.

5.

Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads.

Kumar A, Kinneer K, Masterson L, Ezeadi E, Howard P, Wu H, Gao C, Dimasi N.

Bioorg Med Chem Lett. 2018 Dec 15;28(23-24):3617-3621. doi: 10.1016/j.bmcl.2018.10.043. Epub 2018 Oct 26.

PMID:
30389292
6.

Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells.

Kinneer K, Flynn M, Thomas SB, Meekin J, Varkey R, Xiao X, Zhong H, Breen S, Hynes PG, Fleming R, Bezabeh B, Chen CT, Wetzel L, Chen R, Dimasi N, Tai YT, Anderson KC, Herbst R, Howard PW, Hurt EM, Tice DA.

Leukemia. 2019 Mar;33(3):766-771. doi: 10.1038/s41375-018-0278-7. Epub 2018 Oct 12. No abstract available.

PMID:
30315237
7.

SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.

Kinneer K, Meekin J, Tiberghien AC, Tai YT, Phipps S, Kiefer CM, Rebelatto MC, Dimasi N, Moriarty A, Papadopoulos KP, Sridhar S, Gregson SJ, Wick MJ, Masterson L, Anderson KC, Herbst R, Howard PW, Tice DA.

Clin Cancer Res. 2018 Dec 15;24(24):6570-6582. doi: 10.1158/1078-0432.CCR-18-1300. Epub 2018 Aug 21.

PMID:
30131388
8.

Molecular engineering strategies and methods for the expression and purification of IgG1-based bispecific bivalent antibodies.

Dimasi N, Fleming R, Wu H, Gao C.

Methods. 2019 Feb 1;154:77-86. doi: 10.1016/j.ymeth.2018.08.004. Epub 2018 Aug 11. Review.

PMID:
30102989
9.

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.

Cho S, Zammarchi F, Williams DG, Havenith CEG, Monks NR, Tyrer P, D'Hooge F, Fleming R, Vashisht K, Dimasi N, Bertelli F, Corbett S, Adams L, Reinert HW, Dissanayake S, Britten CE, King W, Dacosta K, Tammali R, Schifferli K, Strout P, Korade M 3rd, Masson Hinrichs MJ, Chivers S, Corey E, Liu H, Kim S, Bander NH, Howard PW, Hartley JA, Coats S, Tice DA, Herbst R, van Berkel PH.

Mol Cancer Ther. 2018 Oct;17(10):2176-2186. doi: 10.1158/1535-7163.MCT-17-0982. Epub 2018 Jul 31.

PMID:
30065100
10.

Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates.

Hinrichs MJM, Ryan PM, Zheng B, Afif-Rider S, Yu XQ, Gunsior M, Zhong H, Harper J, Bezabeh B, Vashisht K, Rebelatto M, Reed M, Ryan PC, Breen S, Patel N, Chen C, Masterson L, Tiberghien A, Howard PW, Dimasi N, Dixit R.

Clin Cancer Res. 2017 Oct 1;23(19):5858-5868. doi: 10.1158/1078-0432.CCR-17-0219. Epub 2017 Jun 19.

11.

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.

Harper J, Lloyd C, Dimasi N, Toader D, Marwood R, Lewis L, Bannister D, Jovanovic J, Fleming R, D'Hooge F, Mao S, Marrero AM, Korade M 3rd, Strout P, Xu L, Chen C, Wetzel L, Breen S, van Vlerken-Ysla L, Jalla S, Rebelatto M, Zhong H, Hurt EM, Hinrichs MJ, Huang K, Howard PW, Tice DA, Hollingsworth RE, Herbst R, Kamal A.

Mol Cancer Ther. 2017 Aug;16(8):1576-1587. doi: 10.1158/1535-7163.MCT-16-0825. Epub 2017 May 18.

12.

Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.

Rios-Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, Marrero A, Chen C, Strout P, Mulgrew K, McGlinchey K, Fleming R, Bezabeh B, Meekin J, Stewart D, Kennedy M, Martin P, Buchanan A, Dimasi N, Michelotti E, Hollingsworth R.

Cancer Res. 2017 May 15;77(10):2686-2698. doi: 10.1158/0008-5472.CAN-16-2854. Epub 2017 Mar 10.

13.

Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.

Dimasi N, Fleming R, Zhong H, Bezabeh B, Kinneer K, Christie RJ, Fazenbaker C, Wu H, Gao C.

Mol Pharm. 2017 May 1;14(5):1501-1516. doi: 10.1021/acs.molpharmaceut.6b00995. Epub 2017 Mar 16.

PMID:
28245132
14.

Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain.

Dimasi N, Fleming R, Sachsenmeier KF, Bezabeh B, Hay C, Wu J, Sult E, Rajan S, Zhuang L, Cariuk P, Buchanan A, Bowen MA, Wu H, Gao C.

MAbs. 2017 Apr;9(3):438-454. doi: 10.1080/19420862.2016.1277301. Epub 2017 Jan 5.

15.

Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.

Bezabeh B, Fleming R, Fazenbaker C, Zhong H, Coffman K, Yu XQ, Leow CC, Gibson N, Wilson S, Stover CK, Wu H, Gao C, Dimasi N.

MAbs. 2017 Feb/Mar;9(2):240-256. doi: 10.1080/19420862.2016.1270492.

16.

Straightforward Glycoengineering Approach to Site-Specific Antibody-Pyrrolobenzodiazepine Conjugates.

Thompson P, Ezeadi E, Hutchinson I, Fleming R, Bezabeh B, Lin J, Mao S, Chen C, Masterson L, Zhong H, Toader D, Howard P, Wu H, Gao C, Dimasi N.

ACS Med Chem Lett. 2016 Sep 20;7(11):1005-1008. eCollection 2016 Nov 10.

17.

Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.

Thompson P, Fleming R, Bezabeh B, Huang F, Mao S, Chen C, Harper J, Zhong H, Gao X, Yu XQ, Hinrichs MJ, Reed M, Kamal A, Strout P, Cho S, Woods R, Hollingsworth RE, Dixit R, Wu H, Gao C, Dimasi N.

J Control Release. 2016 Aug 28;236:100-16. doi: 10.1016/j.jconrel.2016.06.025. Epub 2016 Jun 18.

PMID:
27327768
18.

Biodistribution Analyses of a Near-Infrared, Fluorescently Labeled, Bispecific Monoclonal Antibody Using Optical Imaging.

Peterson NC, Wilson GG, Huang Q, Dimasi N, Sachsenmeier KF.

Comp Med. 2016 Apr;66(2):90-9.

19.

A Nanoparticle Platform To Evaluate Bioconjugation and Receptor-Mediated Cell Uptake Using Cross-Linked Polyion Complex Micelles Bearing Antibody Fragments.

Florinas S, Liu M, Fleming R, Van Vlerken-Ysla L, Ayriss J, Gilbreth R, Dimasi N, Gao C, Wu H, Xu ZQ, Chen S, Dirisala A, Kataoka K, Cabral H, Christie RJ.

Biomacromolecules. 2016 May 9;17(5):1818-33. doi: 10.1021/acs.biomac.6b00239. Epub 2016 Apr 4.

PMID:
27007881
20.

The application of mathematical modelling to the design of bispecific monoclonal antibodies.

van Steeg TJ, Bergmann KR, Dimasi N, Sachsenmeier KF, Agoram B.

MAbs. 2016;8(3):585-92. doi: 10.1080/19420862.2016.1141160. Epub 2016 Feb 24.

21.

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.

Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJ, Bezabeh BZ, Fleming RL, Dimasi N, Feng H, Toader D, Yuan AQ, Xu L, Lin J, Gao C, Wu H, Dixit R, Osbourn JK, Coats SR.

Cancer Cell. 2016 Jan 11;29(1):117-29. doi: 10.1016/j.ccell.2015.12.008. Erratum in: Cancer Cell. 2019 Jun 10;35(6):948-949.

22.

Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides.

Christie RJ, Fleming R, Bezabeh B, Woods R, Mao S, Harper J, Joseph A, Wang Q, Xu ZQ, Wu H, Gao C, Dimasi N.

J Control Release. 2015 Dec 28;220(Pt B):660-70. doi: 10.1016/j.jconrel.2015.09.032. Epub 2015 Sep 24.

PMID:
26387744
23.

Hydrolytically Stable Site-Specific Conjugation at the N-Terminus of an Engineered Antibody.

Thompson P, Bezabeh B, Fleming R, Pruitt M, Mao S, Strout P, Chen C, Cho S, Zhong H, Wu H, Gao C, Dimasi N.

Bioconjug Chem. 2015 Oct 21;26(10):2085-96. doi: 10.1021/acs.bioconjchem.5b00355. Epub 2015 Sep 21.

PMID:
26340339
24.

Development of a Trispecific Antibody Designed to Simultaneously and Efficiently Target Three Different Antigens on Tumor Cells.

Dimasi N, Fleming R, Hay C, Woods R, Xu L, Wu H, Gao C.

Mol Pharm. 2015 Sep 8;12(9):3490-501. doi: 10.1021/acs.molpharmaceut.5b00268. Epub 2015 Aug 4.

PMID:
26176328
25.

A multifunctional bispecific antibody protects against Pseudomonas aeruginosa.

DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK.

Sci Transl Med. 2014 Nov 12;6(262):262ra155. doi: 10.1126/scitranslmed.3009655.

26.

CD19 and CD32b differentially regulate human B cell responsiveness.

Karnell JL, Dimasi N, Karnell FG 3rd, Fleming R, Kuta E, Wilson M, Wu H, Gao C, Herbst R, Ettinger R.

J Immunol. 2014 Feb 15;192(4):1480-90. doi: 10.4049/jimmunol.1301361. Epub 2014 Jan 17.

27.

The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators.

Dimasi N, Gao C, Fleming R, Woods RM, Yao XT, Shirinian L, Kiener PA, Wu H.

J Mol Biol. 2009 Oct 30;393(3):672-92. doi: 10.1016/j.jmb.2009.08.032. Epub 2009 Aug 20.

PMID:
19699208
28.

Structural features of the full-length adaptor protein GADS in solution determined using small-angle X-ray scattering.

Moran O, Roessle MW, Mariuzza RA, Dimasi N.

Biophys J. 2008 Mar 1;94(5):1766-72. Epub 2007 Nov 9.

29.

Expression, crystallization and X-ray data collection from microcrystals of the extracellular domain of the human inhibitory receptor expressed on myeloid cells IREM-1.

Dimasi N, Flot D, Dupeux F, Márquez JA.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Mar 1;63(Pt 3):204-8. Epub 2007 Feb 13.

30.

Active focal segmental glomerulosclerosis is associated with massive oxidation of plasma albumin.

Musante L, Candiano G, Petretto A, Bruschi M, Dimasi N, Caridi G, Pavone B, Del Boccio P, Galliano M, Urbani A, Scolari F, Vincenti F, Ghiggeri GM.

J Am Soc Nephrol. 2007 Mar;18(3):799-810. Epub 2007 Feb 7.

31.

The crystal structure of the extracellular domain of the inhibitor receptor expressed on myeloid cells IREM-1.

Márquez JA, Galfré E, Dupeux F, Flot D, Moran O, Dimasi N.

J Mol Biol. 2007 Mar 23;367(2):310-8. Epub 2007 Jan 10.

PMID:
17275839
33.

Identification and molecular modelling of a novel familial mutation in the SRY gene implicated in the pure gonadal dysgenesis.

Gimelli G, Gimelli S, Dimasi N, Bocciardi R, Di Battista E, Pramparo T, Zuffardi O.

Eur J Hum Genet. 2007 Jan;15(1):76-80. Epub 2006 Oct 25.

35.

Molecular analysis and solution structure from small-angle X-ray scattering of the human natural killer inhibitory receptor IRp60 (CD300a).

Dimasi N, Roessle M, Moran O, Candiano G, Svergun DI, Biassoni R.

Int J Biol Macromol. 2007 Feb 20;40(3):193-200. Epub 2006 Jul 26.

PMID:
16949664
36.

Characterization of oxidation end product of plasma albumin 'in vivo'.

Musante L, Bruschi M, Candiano G, Petretto A, Dimasi N, Del Boccio P, Urbani A, Rialdi G, Ghiggeri GM.

Biochem Biophys Res Commun. 2006 Oct 20;349(2):668-73. Epub 2006 Aug 23.

PMID:
16949044
37.

Expression, refolding and crystallizations of the Grb2-like (GADS) C-terminal SH3 domain complexed with a SLP-76 motif peptide.

Faravelli A, Dimasi N.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006 Jan 1;62(Pt 1):52-5. Epub 2005 Dec 16.

38.

Human natural killer cell receptor functions and their implication in diseases.

Biassoni R, Dimasi N.

Expert Rev Clin Immunol. 2005 Sep;1(3):405-17. doi: 10.1586/1744666X.1.3.405.

PMID:
20476991
39.

Innate immunity in self and infectious nonself recognition.

Biassoni R, Terrazzano G, Dimasi N, Carbone E.

Expert Rev Clin Immunol. 2005 Jul;1(2):187-90. doi: 10.1586/1744666X.1.2.187. No abstract available.

PMID:
20476932
40.

Structural and functional aspects of the Ly49 natural killer cell receptors.

Dimasi N, Biassoni R.

Immunol Cell Biol. 2005 Feb;83(1):1-8. Review.

PMID:
15661035
41.

Entropically assisted carbohydrate recognition by a natural killer cell-surface receptor.

Swaminathan CP, Wais N, Vyas VV, Velikovsky CA, Moretta A, Moretta L, Biassoni R, Mariuzza RA, Dimasi N.

Chembiochem. 2004 Nov 5;5(11):1571-5. No abstract available.

PMID:
15515091
42.
43.

Binding specificity of multiprotein signaling complexes is determined by both cooperative interactions and affinity preferences.

Houtman JC, Higashimoto Y, Dimasi N, Cho S, Yamaguchi H, Bowden B, Regan C, Malchiodi EL, Mariuzza R, Schuck P, Appella E, Samelson LE.

Biochemistry. 2004 Apr 13;43(14):4170-8.

PMID:
15065860
44.

Human natural killer cell receptors: insights into their molecular function and structure.

Biassoni R, Cantoni C, Marras D, Giron-Michel J, Falco M, Moretta L, Dimasi N.

J Cell Mol Med. 2003 Oct-Dec;7(4):376-87. Review.

45.

Structure of the saccharide-binding domain of the human natural killer cell inhibitory receptor p75/AIRM1.

Dimasi N, Moretta A, Moretta L, Biassoni R, Mariuzza RA.

Acta Crystallogr D Biol Crystallogr. 2004 Feb;60(Pt 2):401-3. Epub 2004 Jan 23.

PMID:
14747738
46.

Variable MHC class I engagement by Ly49 natural killer cell receptors demonstrated by the crystal structure of Ly49C bound to H-2K(b).

Dam J, Guan R, Natarajan K, Dimasi N, Chlewicki LK, Kranz DM, Schuck P, Margulies DH, Mariuzza RA.

Nat Immunol. 2003 Dec;4(12):1213-22. Epub 2003 Nov 2.

PMID:
14595439
47.

Expression, crystallization and preliminary crystallographic analysis of the extracellular IgV-like domain of the human natural killer cell inhibitory receptor p75/AIRM1.

Dimasi N, Moretta L, Biassoni R, Mariuzza RA.

Acta Crystallogr D Biol Crystallogr. 2003 Oct;59(Pt 10):1856-8. Epub 2003 Sep 19.

PMID:
14501137
48.

Crystal structure of the Ly49I natural killer cell receptor reveals variability in dimerization mode within the Ly49 family.

Dimasi N, Sawicki MW, Reineck LA, Li Y, Natarajan K, Margulies DH, Mariuzza RA.

J Mol Biol. 2002 Jul 12;320(3):573-85.

PMID:
12096910
49.

MHC class I recognition by Ly49 natural killer cell receptors.

Natarajan K, Dimasi N, Wang J, Margulies DH, Mariuzza RA.

Mol Immunol. 2002 May;38(14):1023-7. Review.

PMID:
11955594
50.

Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination.

Natarajan K, Dimasi N, Wang J, Mariuzza RA, Margulies DH.

Annu Rev Immunol. 2002;20:853-85. Epub 2001 Oct 4. Review.

PMID:
11861620

Supplemental Content

Loading ...
Support Center